TDIS^TM

Tardive Dyskinesia Impact Scale

The Tardive Dyskinesia Impact Scale is the first and only psychometrically validated patient-reported outcome (PRO) specific for tardive dyskinesia (TD) developed by an expert panel of TD clinicians with input from patients and caregivers¹. The 11-item questionnaire assesses the impact of TD on patients' physical and socioemotional functioning over the previous 7 days, providing insight into how TD affects daily life from the patient's perspective.

The TDIS generates Physical Impact and Socioemotional Impact domain scores, as well as an overall total score, with higher scores indicating greater disease impact. Its measurement properties were developed and evaluated in accordance with principles outlined in the FDA's Patient Focused Drug Development guidance documents. The TDIS was included as a primary endpoint in a Phase 4, open-label clinical trial that enrolled patients with mild, moderate, and severe TD.

The TDIS is approved for clinical practice only. Please note that the TDIS is not approved for duplication, dissemination, modification, or use for research, academic, or commercial purposes without express written permission of Neurocrine Biosciences, Inc.

References: 1. Farber RH, Stull DE, Witherspoon B, et al. The Tardive Dyskinesia Impact Scale (TDIS), a novel patient-reported outcome measure in tardive dyskinesia: development and psychometric validation. J Patient Rep Outcomes. 2024;8(1):2.